Treating cancer with dissimilar disease

By Dr. Guillermo Zamora, a surgeon UAG, Homeopath (Dhom. Med) by the Institute for Homoeopathic Medicine.


For those who question the strength of the inductive method of reasoning applied to medicine proposed by Hahnemann, put as an example if not its antithesis, if it is unduly partial observation of an event, the report that for several days been going on for the journal Public Library of Science Pathogens [1] and has been published in various journals, conferences, websites, and magazines [2].

This report mentions that a genetically modified virus [“oncolytic” herpes simplex virus (HSV)] has been created, and is able to block the spread of ovarian cancer and breast cancer in mice. It seems important to mention that different sources of conventional medicine, have been saying this for several years.

Chief Scientist, Professor Gabriella Campadelli-Fiume, University of Bologna in Italy, said: “Many laboratories worldwide are using more specific viruses as weapons against cancer cells, called oncolytic viruses.”

“Safety concerns prevailed so far, and all oncolytic herpes virus now in clinical trials are weakened viruses, effective only against a fraction of tumors.”

“We were the first to obtain a reprogrammed herpes virus to enter positive tumor cells, unable to infect other cells, but retains the same ability to kill in order that the wild-type HSV.”

According to Dr. Kevin Harrington, Institute of Cancer Research in London, who is leading oncolytic virotherapy studies [3], has been obtained “success” in up to 93% of cases in which the virus (and other viruses such as reovirus and adenovirus) has been modified to not infect healthy tissue (?) and according to the studies could become successful treatment in the fight against head and neck cancer.

With FDA approval, studies (including multicenter) are carried out in different phases using intratumoral injection in order to evaluate the response of colony stimulating factor-granulocyte macrophage [JS1/34.5-/47-/granulocyte -macrophage colony-stimulating factor (GM-CSF)] in different types of advanced cancer. Studies may include combinations of chemotherapy with cyclophosphamide, docetaxel, 3-AP Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), radiation therapy, or combined chemoradiation in which studies show is “synergy” between all therapies. Side effects such as anemia, nausea, and fatigue are often reported, and neutropenia. One speaks of proviral states as vascular endothelial growth factor (vascular endothelial growth factor or VEGF) during which the reovirus can replicate oncolytic administered systemically in the endothelium, thereby inducing immune-mediated vascular collapse with significant antitumor properties.

Many studies show how are you amazing results with proven results in the treatment of certain cancers. However, the long term effects of drug-biological treatments, dependence and the tendency to acquire another disease state or immune weakness, are some maxims that should worry us. No medical intervention or treatment should be given without a long period of experimentation and testing (*). A Hahnemann It took eight years before he started dealing with Homoeopathy. There are many books, documents and writings and research experiments on the reactions, similarities, and results before he carefully follow each step with your therapy.

(*) This warning applies also for studies with the name “Homoeopathy” is conducted for cancer treatment (for example the protocol Banerji Homeopathic Research Foundation), especially when real has not been practiced homeopathy for decades for most of the “homeopathic”.

Something that has not been taken into account is that one thing is the infectious agent with whom you work for any purpose, and one is the reaction-disease so mild, moderate or severe body generates all contacts that agent. Any modified agent however, can not be discriminative enough not to cause a reaction in the center of the life force (wherever it is), as we saw with the immediate side effects reported as anemia, nausea, fatigue and neutropenia.

The experimental study is developed with the herpes virus, derived from observation (as I said at the beginning, unduly partial) that people with cancer and at the same time acquire or come into contact with people infected with the herpes virus appear stop development of its initial cancerous state, and even reverse it [4]. (I translate an extract of the reference number 4 on the history of oncolytic therapy, for the convenience of our readers)

“It seems that the use of viruses in cancer treatment was not the result of some insightful theory of alternative therapy, but rather only derived from the observation that, occasionally, cancer patients who contracted an infectious disease had brief periods clinical remission. “

So, we put a lot of attention. We must not lose the entire complex under which certain conditions are favoring the experimental subjects, who were either inmunosuprime (even when it is intended to search a localized immune response), or causes them to weaken their disease through chemo and / or radiation while trying to “attack” the tumor with the modified virus. This means that protocols require that artificially weaken, suppress or maintain and produce a susceptibility to opportunistic infectious miasm widely known, but enough to make it amended as yet unknown. With this, it will be predicted drug dependence or ultimately death because desarmonizado balance that sustains life. We will see later why.

This herpes and cancer research leads me to remember what Hahnemann had observed about through simple inductance and I would have liked to have been taken into account by the researchers (or perhaps if they knew about it?). This would comment that we do not object to people using their preferred therapy or oppose personal opinions. What we would like is that these observations are considered under Baconian establish a new era in science as applied to medicine.

I can not leave out, mention the fact that prior experimentation on animals has serious drawbacks, including:

  • Animals can not express subjective symptoms produced during the experiment.
  • Infective agents (read infecting agent perspective Hahnemanniana) act differently in each species.
  • Humans and animals react differently to these infectious agents.
  • There are substances in animals may be harmless, while for men can be highly toxic and vice versa.
  • Man or animal (host) can act as a reservoir and in turn so individualized in each body of each species cause changes (mutations) to infective agents making them more potent complexes, reactivándolos (eg after attenuated) or increasing their virulence ( **).

(**) Vaccines may also be applied to the same vial containing three viruses or vaccines contaminated with unknown viruses. [5, 6.7 to cite some references, but there is enough hemerography about]

As I mentioned before and want to accept it or not researchers oncolytic viral therapy (they did not know, did not understand, did not care or did purposely. No) [4], for almost 200 years, Hahnemann had already observed in As regards to the reaction-disease, three circumstances where two dissimilar diseases coexist in the body of a human being, I quote two of those three circumstances with some of his remarks and references:

Aphorism § 38, Organon, 6th. edition

“II. – New to dissimilar disease is the strongest. – In this case the disease under which the patient lived primitively, being the weakest, will be arrested and suspended by the emergence of stronger, until it cross its course or be cured, then the old reappears uncured.

  • “As noted Tulpius 72 two children suffering from some form of epilepsy, were free of attacks after being infested with ringworm (instep), but as soon as the eruption of epilepsy head disappeared again as before. (72 Obs., lib. i, obs. 8)


  • Scabies, as noted Schopf 73 submitted scurvy disappeared, but after it healed, that reappeared. (72 Obs., lib. i, obs. 8)


  • So also remained stationary pulmonary tuberculosis patient being attacked by a violent typhus, but continued their march after typhus ran its course. 74   (74 Chevalier, in Hufeland’s Neuesten Annalen der Französiche, Heiljunde, ii, p. 192)


  • When the measles and smallpox together dominate, and both attack the same child, measles-existing, generally is contained by smallpox appeared later; measles does not end until it ends its course smallpox, but not uncommon it happens that the smallpox infection is suspended for four days by the supervening of measles, after which scaling complete your smallpox, as observed by Manget. 76 (76 In Edimb. Med Comment., Pt. I, I)


  • So with all dissimilar diseases, the strongest stops development of the weakest (if not complicated which is rare in acute diseases), but never a cure to the other. “(My emphasis)


The aphorism § 40, 6th Organon. Editing refers to a combined response (or response miasmatic disease combined mutant)

“III. – The new disease, after he had worked a long time in the body, finally joins that is unlike the former, and forms with it a complex disease, so that each occupies a special location in the body, ie organs peculiarly adapted to it and only that particular location belongs, while leaving the remaining organs other disease that is unlike … For two dissimilar diseases can not be destroyed, can not be cured to one another … not However, there have also been major epidemics of this kind, in which two dissimilar acute and, in rare cases, have occurred simultaneously in one and the same body, and combined, as it were, for a short time with each other … then, though not completely incurable, but can be transformed into health with very great difficulty. “

  • “Rainey 86 witnessed the simultaneous occurrence of measles and smallpox in two girls. (86 Edinb. Med Comment, iii, p. 480)
  • J. Maurice 87 throughout its practice observed only two cases of this kind. (87 in Phys Med and Journ., 1,805)
  • Similar cases are found in the works of Ettmüller 88 and in the writings of some others. (88 Opera, ii, pi, chap. 10)
  • Lencker 89 vaccine was go full term together with measles and purple. (89 Hufeland’s Journal, X v ii) “


This latter circumstance applies for malnourished patients, and / or with certain addictions, and / or debilitating conditions, and / or in immunosuppressed patients, etc. A clear example of this would be all diseases “new” appearance as acquired immunodeficiency syndrome (AIDS), in which you can combine various diseases caused by two or more types of the herpes family (***) and microorganisms and other viral, bacterial, fungal, etc..

(***) In the last 100 years have discovered 8 different types of herpes.

1.-TYPE herpes simplex virus I.

2.-Herpes Simplex Virus Type II

3.-varicella-zoster virus.

4.-Epstein-Barr virus.


6.-herpesvirus-6-6-B AY. (HHV-6)

7.-herpesvirus 7 (HHV-7)

8.-human herpesvirus 8 (Kaposi’s sarcoma)

If we reflect the foregoing, we find that Hahnemann makes complete observations (and NO partial), deep and detailed the circumstances between two dissimilar diseases coexist, including the aftermath of the same, so we can see that the inductance in science, observe the experienced (even from the same accident or toxicity), helps predict the outcome of an event. Take into account the principles established by Hahnemann in the Organon for experimentation and the coexistence of two dissimilar diseases is not a minor thing. Accept and understand our limitations, our achievements, and the consequences of such applications in medicine is vital to our future and wellbeing.



[2] Huffingtonpost, Herpes Virus Could Be Key To Breast And Ovarian Cancer Treatment, The Huffington Post UK | Posted: 31/01/2013 22:16 GMT

GM virus blocks spread of cancer, Press Association – Thu, Jan 31, 2013, yahoo news.

Herpes virus, “new weapon” against cancer Join BBC Science, August 2, 2010 – 13:39 GMT

The herpes virus shows promise in treating breast cancer, Isaude, Science and Technology, published on 26/10/2011 at 13h58: 00

HERPES VIRUS SHOWS PROMISE IN TREATING EARLY TRIPLE-NEGATIVE BREAST CANCER Oncolytic viral therapy shows great potential for treating an aggressive form of breast cancer, News from the Clinical Congress, Yuman Fong, MD, FACS Sepideh Gholami, MD, Monday, October 24, 1:00 pm

[3] Donnelly, OG., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R. & Melcher, AA. (2012) Recent Clinical Experience with oncolytic Viruses Current Pharmaceutical Biotechnology, Vol.13 (9), pp.1834-1841, ISSN: 1389-2010.

Adair, RA., Roulstone, V., Scott, KJ., Morgan, R., Nuovo, GJ., Fuller, M., Beirne, D., West, EJ., Jennings, VA., Rose, A., et al. (2012) Cell Carriage, Delivery, and Selective Replication of an oncolytic virus in Tumor in Patients Science Translational Medicine, Vol.4 (138), ISSN: 1946-6234.

Karapanagiotou, MS., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, ME., Larkin, J., Syrigos, KN., et al. (2012) Phase I / II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with Advanced Malignancies. Clin Cancer Res, Vol.18 (7), pp.2080-2089, ISSN: 1078-0432 .

Simpson, GR., Horvath, A., Annels, NE., Pencavel, T., Metcalf, S., Seth, R., Peschard, P., Price, T., Coffin, RS., Mostafid, H., et al. (2012) Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for bladder cancer Surface British Journal of Cancer, Vol.106 (3), pp.496-507, ISSN: 0007-0920 .

Kottke, T., Chester, J., Ilett, E., Thompson, J., Diaz, R., Coffey, M. Selby, P., Nuovo, G., Pulido, J., Mukhopadhyay, D., et al. (2011) Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic oncolytic virotherapy MOL THER, Vol.19 (10), pp.1802-1812, ISSN: 1525-0016.

Heinemann, L., Simpson, GR., Boxall, A., Kottke, T., Relph, KL., Vile, R., Melcher, A., Prestwich, R., Harrington, KJ., Morgan, R., et al. (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer BMC CANCER, Vol.11 ISSN: 1471-2407.

Touchefeu, Y., Vassaux, G. & Harrington, KJ. (2011) oncolytic viruses in radiation oncology Radiother Oncol, vol.99 (3), pp.262-270, ISSN: 0167-8140.

Ilett, EJ., Barcena, M., Errington-Mais, F., Griffin, S., Harrington, KJ., Pandha, HS., Coffey, M., Selby, PJ., Limpens, RWAL., Mommaas, M . et al. (2011) Internalization of oncolytic Reovirus by Human Dendritic Cell Carriers from the Virus Neutralization Protects Clin Cancer Res, Vol.17 (9), pp.2767-2776, ISSN: 1078-0432.

Willmon, C., Diaz, RM., Wongthida, P., Galivo, F., Kottke, T., Thompson, J., Albelda, S., Harrington, K., Melcher, A. & Vile, R. (2011) Vesicular Stomatitis Virus-induced Suppressor Cells Immune Antagonism Between Intratumoral oncolytic Generate Virus and Cyclophosphamide Mol Ther, Vol.19 (1), pp.140-149, ISSN: 1525-0016.

Senzer, NN., Kaufman, HL., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) Phase II Clinical Trial of a Granulocyte-macrophage colony-stimulating factor-Encoding, Second-Generation oncolytic herpesvirus in unresectable Patients With Metastatic Melanoma J CLIN ONCOL, Vol.27 (34), pp.5763-5771, ISSN: 0732-183x.

Harrington, KJ. (2010) Topical treatment for oral Cancers Winners and Losers and oncolytic adenoviruses: who should be down in the mouth? GENE THER, Vol.17 (12), pp.1421-1422, ISSN: 0969-7128.

Harrington, KJ., Hingorani, M., Tanay, MA., Hickey, J., Bhide, SA., Clarke, PM., Renouf, LC., Thway, K., Sibtain, A., McNeish, IA., et al. (2010) Phase I / II Study of oncolytic HSVGM-CSF in Combination with Cisplatin in Untreated Radiotherapy and Stage III / IV Squamous Cell Cancer of the Head and Neck Clin Cancer Res, Vol.16 (15), pp.4005 -4015, ISSN: 1078-0432.

Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, KJ., McNeish, IA. & Vassaux, G. (2010 ) Assessment of the Na / I symporter gene as a reporter to visualize oncolytic adenovirus propagation in peritoneal Tumours Eur J Nucl Med MOL I, Vol.37 (7), pp.1377-1385, ISSN: 1619-7070.

Kottke, T., Hall, G., Pulido, J., Diaz, RM., Thompson, J., Chong, H., Selby, P., Coffey, M., Pandha, H., Chester, J., et al. (2010) Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of tumors in mice Established J CLIN INVEST, Vol.120 (5), pp.1551-1560, ISSN: 0021-9738.

Harrington, KJ., Vile, RG., Melcher, A., Chester, J. & Pandha, HS. (2010) Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev, Vol.21 (2-3), pp.91-98.

Senzer, NN., Kaufman, HL., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) Phase II Clinical Trial of a Granulocyte-macrophage colony-stimulating factor-Encoding, Second-Generation oncolytic herpesvirus in unresectable Patients With Metastatic Melanoma J CLIN ONCOL, Vol.27 (34), pp.5763-5771, ISSN: 0732-183x.

Willmon, C., Harrington, K. Kottke, T., Prestwich, R. Melcher, A. & Vile, R. (2009) Cell Carriers for oncolytic Viruses: Fed Ex for Cancer Therapy MOL THER, Vol.17 (10), pp.1667-1676, ISSN: 1525-0016.

Prestwich, RJ., Errington, F., Steele, LP., Ilett, EJ., Morgan, RSM., Harrington, KJ., Pandha, HS., Selby, PJ., Vile, RG. & Melcher, AA. (2009) Reciprocal Human Dendritic Cell-Induced Natural Killer Cell Interactions Following Antitumor Activity Tumor Cell Reovirus Infection by oncolytic J Immunol, Vol.183 (7), pp.4312-4321, ISSN: 0022-1767.

Pandha, HS., Heinemann, L., Simpson, GR., Melcher, A., Prestwich, R., Errington, F., Coffey, M., Harrington, KJ. & Morgan, R. (2009) Synergistic Effects of oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma CLIN CANCER RES, Vol.15 (19), pp.6158-6166, ISSN: 1078-0432.

Prestwich, RJ., Errington, F., Diaz, RM., Pandha, HS., Harrington, KJ., Melcher, AA. & Vile, RG. (2009) The Case of oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon HUM GENE THER, Vol.20 (10), pp.1119-1132, ISSN: 1043-0342.

Prestwich, RJ., Ilett, EJ., Errington, F., Diaz, RM., Steele, LP., Kottke, T., Thompson, J., Galivo, F., Harrington, KJ., Pandha, HS., et al. (2009) Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Replication Oncolysis and CLIN CANCER RES, Vol.15 (13), pp.4374-4381, ISSN: 1078-0432.

Pandha, H., Melcher, A., Harrington, K. & Vile, R. (2009) oncolytic Viruses: Time to Compare, Contrast, and Combine? MOL THER, Vol.17 (6), pp.934-935, ISSN: 1525-0016.

Ilett, EJ., Prestwich, RJ., Kottke, T., Errington, F., Thompson, JM., Harrington, KJ., Pandha, HS., Coffey, M., Selby, PJ., Vile, RG., et al. (2009) Dendritic cells and T cells deliver Tumour killing oncolytic DESPITE reovirus for pre-existing anti-viral immunity Gene Ther, Vol.16 (5), pp.689-699, ISSN: 0969-7128.

Kottke, T., Thompson, J., Diaz, RM., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K. & Vile, RG. (2009) Improved Systemic Delivery of Established Tumors to Reovirus oncolytic Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2 Clin Cancer Res, Vol.15 (2), pp.561-569, ISSN: 1078 – 0432.

Prestwich, RJ., Errington, F., Ilett, EJ., Morgan, RSM., Scott, KJ., Kottke, T., Thompson, J., Morrison, EE., Harrington, KJ., Pandha, HS., et al. (2008) Tumor Infection by oncolytic Reovirus Primes Adaptive Antitumor Immunity CLIN CANCER RES, Vol.14 (22), pp.7358-7366, ISSN: 1078-0432.

Prestwich, RJ., Harrington, KJ., Pandha, HS., Vile, RG., Melcher, AA. & Errington, F. (2008) oncolytic viruses: a novel form of immunotherapy EXPERT ANTICANC REV, Vol.8 (10), pp.1581-1588, ISSN: 1473-7140.

Harrington, KJ., Melcher, A., Vassaux, G., Pandha, HS. & Vile, RG. (2008) Exploiting Synergies Between radiation and oncolytic viruses. Curr Opin Mol Ther, Vol.10 (4), pp.362-370, ISSN: 1464-8431.

Prestwich, RJ., Harrington, KJ., Vile, RG. & Melcher, AA. (2008) immunotherapeutic potential of oncolytic virotherapy LANCET ONCOL, Vol.9 (7), pp.610-612, ISSN: 1470-2045.

Kottke, T., Galivo, F., Wongthida, P., Diaz, RM., Thompson, J., Jevremovic, D., Barber, GN., Hall, G., Chester, J., Selby, P., et al. (2008) Treg depletion-enhanced IL-2 therapy of treatment Facilitates Established tumors delivered systemically using oncolytic virus Mol Ther, Vol.16 (7), pp.1217-1226, ISSN: 1525-0016.

White, CL., Twigger, KR., Vidal, L., De Bono, JS., Coffey, M., Heinemann, L., Morgan, R., Merrick, A., Errington, F., Vile, RG. , et al. (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther, Vol.15 (12), pp.911-920.

Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, RM., Thompson, J., Ryno, P., Barber, GN., Chester, J., et al. (2008) Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, immunotherapy and virotherapy oncolytic Nat Med, Vol.14 (1), pp.37-44, ISSN: 1078-8956.

Hu, JC., Coffin, RS., Davis, CJ., Graham, NJ., Groves, N., Guest, PJ., Harrington, KJ., James, ND., Love, CA., McNeish, I., et al. (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res, Vol.12 (22), pp.6737-6747, ISSN: 1078-0432.

[4] NATURE, Molecular Therapy (2007) 15 4, 651-659 doi: 10.10, “History of oncolytic Viruses: Genesis to Genetic Engineering”, Elizabeth Kelly and Stephen J Russell:

“It Appears That the use of viruses in the treatment of cancer was not the result of some perspicacious theory of an alternative therapy but Rather stemmed from the observation just That, occasionally, Contracted cancer patients who went into an infectious disease brief periods of clinical remission . “

[5] Modulation of immune responses during canine distemper virus infection: implications for therapeutic and vaccine development, Céspedes PF *, P Cruz, CO Navarro, Faculty of Veterinary and Animal Sciences, Laboratory of Animal Virology, University of Chile , Santiago, Chile. Arch Med Vet 42, 15-28 (2010):

“This last statement is based on evidence of the ability of the attenuated vaccine virus to revert to virulence so fleeting and cause lethal encephalitis in dogs following immunization and, similarly, a multisystem box of 90-100% morbidity and lethality in ferrets blacklegged (Mustela putorius furo) (Summers and Appel 1994, von Messling et al 2003). “

[6] Reverse Genetics for Live Attenuated Virus Vaccine Development Kun Yao, * and Zaishi Wang

“… An attenuated virus can still replicate in the Vaccinated Individuals, Therefore, the virus has the potential to revert to virulent phenotypes. Moreover, some of live vaccines can be Transmitted from the person to non immunized Vaccinated Individuals … “

“These are particularly important safety Concerns for Certain human RNA human parainfluenza viruses Such as virus (PIV), respiratory syncytial virus (RSV) and HIV, since viruses These RNA, RNA-dependent RNA Whose polymerases do not have a proofreading function and a high Could Occur During mutation rate virus replication. “

[7] Altered Virulence of Vaccine Strains of Measles Virus after Prolonged Replication in Human Tissue, Alexandra Valsamakis et al, J Virol. October 1999, 73 (10): 8791-8797.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.